[go: up one dir, main page]

DK3408382T3 - Onkolytiske virale vektorer og anvendelser deraf - Google Patents

Onkolytiske virale vektorer og anvendelser deraf Download PDF

Info

Publication number
DK3408382T3
DK3408382T3 DK17704150.6T DK17704150T DK3408382T3 DK 3408382 T3 DK3408382 T3 DK 3408382T3 DK 17704150 T DK17704150 T DK 17704150T DK 3408382 T3 DK3408382 T3 DK 3408382T3
Authority
DK
Denmark
Prior art keywords
viral vectors
oncolytic viral
oncolytic
vectors
viral
Prior art date
Application number
DK17704150.6T
Other languages
English (en)
Inventor
Kenneth P Greenberg
Mitchell H Finer
Original Assignee
Oncorus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncorus Inc filed Critical Oncorus Inc
Application granted granted Critical
Publication of DK3408382T3 publication Critical patent/DK3408382T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK17704150.6T 2016-01-27 2017-01-27 Onkolytiske virale vektorer og anvendelser deraf DK3408382T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662287619P 2016-01-27 2016-01-27
PCT/US2017/015417 WO2017132552A1 (en) 2016-01-27 2017-01-27 Oncolytic viral vectors and uses thereof

Publications (1)

Publication Number Publication Date
DK3408382T3 true DK3408382T3 (da) 2022-06-20

Family

ID=57995301

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17704150.6T DK3408382T3 (da) 2016-01-27 2017-01-27 Onkolytiske virale vektorer og anvendelser deraf

Country Status (18)

Country Link
US (3) US10391132B2 (da)
EP (2) EP4089166A1 (da)
JP (4) JP2019508063A (da)
KR (1) KR20180136435A (da)
CN (2) CN108884448B (da)
AR (1) AR107469A1 (da)
AU (1) AU2017212713B2 (da)
BR (1) BR112018015390A2 (da)
CA (1) CA3011933A1 (da)
DK (1) DK3408382T3 (da)
ES (1) ES2919953T3 (da)
IL (2) IL260790B (da)
MX (1) MX2018009126A (da)
PT (1) PT3408382T (da)
RU (2) RU2021114137A (da)
SG (2) SG10202107138TA (da)
TW (1) TWI798168B (da)
WO (1) WO2017132552A1 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3408382T3 (da) 2016-01-27 2022-06-20 Oncorus Inc Onkolytiske virale vektorer og anvendelser deraf
CN109072255A (zh) * 2016-04-08 2018-12-21 克里斯托生物技术股份有限公司 用于治疗皮肤的伤口、病症和疾病的组合物和方法
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
US10682425B2 (en) 2016-12-14 2020-06-16 The Regents Of The University Of California Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
WO2018194089A1 (ja) * 2017-04-19 2018-10-25 国立大学法人東京大学 遺伝子改変コクサッキーウイルス及び医薬組成物
CA3059480A1 (en) * 2017-04-28 2018-11-01 Toray Industries, Inc. Kit, device, and method for detecting ovarian tumor
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
US20200308550A1 (en) 2017-09-11 2020-10-01 Imba - Institut Für Molekulare Biotechnologie Gmbh Tumor organoid model
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
CN107723367A (zh) * 2017-10-27 2018-02-23 青岛大学 miRNA‑885‑3p的应用和应用其的产品
CN107674918A (zh) * 2017-11-10 2018-02-09 上海交通大学医学院 has‑mir‑195‑5p作为生物标志物在制备肺癌诊断试剂盒中的应用
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
EP4008333A1 (en) 2018-02-19 2022-06-08 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
US11739350B2 (en) 2018-04-10 2023-08-29 Ottawa Hospital Research Institute MicroRNA-based compositions and methods used in disease treatment
US12036256B2 (en) * 2018-04-13 2024-07-16 Regeneron Pharmaceuticals, Inc. Adoptive cellular therapy
CN108707625B (zh) * 2018-07-03 2021-09-21 云笛生物科技有限公司 mir-124和HER2-shRNA双基因表达盒病毒载体、构建方法、病毒、应用
CN109091492A (zh) * 2018-08-02 2018-12-28 广州安镝声生物医药科技有限公司 lncRNA H19的靶miRNA miR-106b-5p及其应用
CN109091491A (zh) * 2018-08-02 2018-12-28 广州安镝声生物医药科技有限公司 lncRNA H19的靶miRNA miR19a-3p及其应用
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
WO2020102285A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
TWI690597B (zh) * 2018-11-14 2020-04-11 國立中央大學 泌尿上皮癌的檢測套組及檢測方法
US20200171110A1 (en) * 2018-11-29 2020-06-04 Virogin Biotech Canada Ltd Hsv vector with reduced neurotoxicity
KR20200069259A (ko) * 2018-12-06 2020-06-16 국립암센터 nc886을 포함하는 암살상 바이러스 활성 증진 또는 생산 증진용 조성물
BR112021013155A2 (pt) * 2019-01-04 2021-09-14 Oncorus, Inc. Polinucleotídeos de rna encapsulados e métodos de uso
CN109762903B (zh) * 2019-01-31 2022-02-01 山东大学齐鲁医院 miR-1246和/或TERF2IP在诊治胶质瘤中的应用
WO2020185298A1 (en) * 2019-03-14 2020-09-17 Massachusetts Institute Of Technology Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof
CN110283794B (zh) * 2019-05-30 2021-04-23 伍泽堂 重组溶瘤病毒以及制备方法、应用和药物
CN112011570B (zh) * 2019-05-31 2023-04-18 北京合生基因科技有限公司 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
EP3999853A1 (en) * 2019-07-16 2022-05-25 Université Côte d'Azur Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof
CN114514323A (zh) * 2019-08-05 2022-05-17 复诺健生物科技加拿大有限公司 遗传修饰的肠病毒载体
CN110468132B (zh) * 2019-08-15 2022-11-25 西南大学 一种sgRNA及转基因表达载体、表达品系、筛选方法
CN110433171B (zh) * 2019-08-20 2022-08-19 中山大学附属第六医院 miRNA-1293在制备抗结直肠肿瘤药物中的应用
CA3157063A1 (en) 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
KR102320430B1 (ko) * 2020-01-29 2021-11-03 서울대학교병원 수모세포종에 대한 miR-135b, miR-135a 및 이들의 표적 유전자 AMOTL2의 용도
US20230133209A1 (en) * 2020-04-14 2023-05-04 Eidgenössische Technische Hochschule Zürich Cell classifier circuits and methods of use thereof
CN113583977A (zh) * 2020-04-30 2021-11-02 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
US20230277633A1 (en) * 2020-06-05 2023-09-07 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical composition of enzymes and viruses and application thereof
US20230242994A1 (en) * 2020-07-10 2023-08-03 Shanghai Miran Biotech Co., Ltd. Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof
MX2023001187A (es) 2020-07-31 2023-04-04 Combined Therapeutics Inc Composiciones y métodos para una vacunación mejorada.
US20240252564A1 (en) * 2020-11-13 2024-08-01 Technische Universität Berlin Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas
CN116744951A (zh) * 2020-12-25 2023-09-12 苏州系统医学研究所 一种包含溶瘤病毒的组合物及其在肿瘤治疗中的应用
US20250049867A1 (en) * 2021-08-31 2025-02-13 Virogin Biotech Canada Ltd. Engineered oncolytic herpesviruses
CN113637761B (zh) * 2021-10-15 2025-01-24 北京百奥思科生物医学技术有限公司 用于黑色素瘤诊断和治疗的miRNA标志物及其相关产品
WO2023142040A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd. Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
CN115381849B (zh) * 2022-06-27 2024-07-26 浙江大学 抗口腔肿瘤药物活性成分及其用途
KR102726438B1 (ko) * 2022-11-29 2024-11-06 주식회사 신렉스 암 세포를 표적으로 하는 복수 개의 miRNA를 발현하도록 유전적 조작된 박테리아 균주

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
DK0641192T3 (da) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Anordning til transmucosal lægemiddelafgivelse
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
EP1037991B1 (en) 1997-12-17 2005-09-28 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
JP4212897B2 (ja) 2001-03-27 2009-01-21 具紀 藤堂 ウイルスおよび治療法におけるそれらの使用
US20020187126A1 (en) 2001-04-06 2002-12-12 Mount Sinai School Of Medicine Methods for viral oncoapoptosis in cancer therapy
JP2005523681A (ja) 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
GB0406389D0 (en) 2004-03-22 2004-04-21 Istituto Superiore Di Sanito Recombinant herpes simplex virus and uses therefor
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US20080160031A1 (en) 2005-01-17 2008-07-03 Viralytics Limited Method and Composition for Treatment of Neoplasms
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
CA2619833C (en) 2005-08-26 2017-05-09 Danisco A/S Use of crispr associated genes (cas)
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
ZA200900787B (en) 2006-08-11 2010-05-26 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
US8586028B2 (en) 2007-05-09 2013-11-19 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
EP2293804B1 (en) 2008-05-29 2013-05-22 Alma Mater Studiorum -Universita' di Bologna Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010054108A2 (en) 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
EP2362915B1 (en) 2008-11-07 2016-12-21 DuPont Nutrition Biosciences ApS Bifidobacteria crispr sequences
AU2010223888A1 (en) 2009-03-13 2011-10-06 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
US20130071430A1 (en) 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
EP2630156B1 (en) 2010-10-20 2018-08-22 DuPont Nutrition Biosciences ApS Lactococcus crispr-cas sequences
EP2702160B1 (en) 2011-04-27 2020-05-27 Amyris, Inc. Methods for genomic modification
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
ES2671728T3 (es) 2011-10-11 2018-06-08 Universität Zürich Prorektorat Mnw Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2591796A1 (en) 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013109604A1 (en) * 2012-01-19 2013-07-25 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
CN104284669A (zh) 2012-02-24 2015-01-14 弗雷德哈钦森癌症研究中心 治疗血红蛋白病的组合物和方法
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US10261083B2 (en) 2013-01-04 2019-04-16 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
CA2915795C (en) 2013-06-17 2021-07-13 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
US10174341B2 (en) 2013-07-17 2019-01-08 University of Pittsburgh—of the Commonwealth System of Higher Education Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
HUE045108T2 (hu) 2014-07-16 2019-12-30 Transgene Sa Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US10083137B2 (en) 2015-04-02 2018-09-25 Atmel Corporation Peripheral interface circuit for serial memory
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
DK3400291T4 (da) 2016-01-08 2024-04-02 Replimune Ltd Manipuleret virus
DK3408382T3 (da) 2016-01-27 2022-06-20 Oncorus Inc Onkolytiske virale vektorer og anvendelser deraf
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
US10821140B2 (en) 2016-04-22 2020-11-03 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
ES2972406T3 (es) 2016-08-01 2024-06-12 Virogin Biotech Canada Ltd Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
CA3033613A1 (en) 2016-08-09 2018-02-15 Almohanad ALKAYYAL Oncolytic rhabdovirus expressing il12
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
WO2018085461A1 (en) 2016-11-01 2018-05-11 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF

Also Published As

Publication number Publication date
ES2919953T3 (es) 2022-07-29
US11452750B2 (en) 2022-09-27
EP3408382A1 (en) 2018-12-05
IL290102A (en) 2022-03-01
RU2749050C2 (ru) 2021-06-03
JP2023001236A (ja) 2023-01-04
AU2017212713B2 (en) 2023-01-19
RU2018130673A (ru) 2020-02-28
US20230115116A1 (en) 2023-04-13
US20180339004A1 (en) 2018-11-29
JP2024052881A (ja) 2024-04-12
KR20180136435A (ko) 2018-12-24
IL290102B2 (en) 2023-04-01
TW201730335A (zh) 2017-09-01
CN108884448B (zh) 2022-12-30
IL260790B (en) 2022-03-01
SG10202107138TA (en) 2021-08-30
CN116904404A (zh) 2023-10-20
JP2021119797A (ja) 2021-08-19
JP7174109B2 (ja) 2022-11-17
US10391132B2 (en) 2019-08-27
SG11201806134SA (en) 2018-08-30
EP4089166A1 (en) 2022-11-16
CA3011933A1 (en) 2017-08-03
WO2017132552A1 (en) 2017-08-03
AU2017212713A1 (en) 2018-07-26
BR112018015390A2 (pt) 2018-12-18
AR107469A1 (es) 2018-05-02
RU2018130673A3 (da) 2020-05-19
EP3408382B1 (en) 2022-03-23
MX2018009126A (es) 2019-08-21
RU2021114137A3 (da) 2021-09-10
US20200147156A1 (en) 2020-05-14
RU2021114137A (ru) 2021-05-25
IL290102B (en) 2022-12-01
CN108884448A (zh) 2018-11-23
TWI798168B (zh) 2023-04-11
PT3408382T (pt) 2022-06-27
JP2019508063A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
DK3408382T3 (da) Onkolytiske virale vektorer og anvendelser deraf
IL271993A (en) Viral vectors of cell lysis and their uses
IL282985B (en) Modified oncolytic viurs
DK3247722T3 (da) Cytomegalovirusantigener og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3265571T3 (da) Fler-vektorsystem og anvendelse heraf
DK3380620T3 (da) Optimerede lentivirale transfervektorer og anvendelse heraf
EP3577132A4 (en) ONCOLYTIC VIRUS THERAPY
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
EP3518947C0 (en) Optimized oncolytic viruses and uses thereof
DK3562946T3 (da) Oncolytiske virusser og terapeutiske molekyler
DK3448419T3 (da) Interferon-beta-antistoffer og anvendelser deraf
DK3436434T3 (da) Indolin-analoger og anvendelser deraf
DK3113795T3 (da) Rekombinante virale isfahan-vektorer
DK3630143T5 (da) Onkolytisk virus og fremgangsmåde
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3291841T3 (da) Onkolytisk hsv1-vektor og fremgangsmåder
DK3189050T3 (da) Antivirale midler og anvendelser deraf
HK1255099A1 (zh) 重組溶瘤病毒及其用途
DK3129037T3 (da) Onkolytiske koppevirusvektorer
EP3624825A4 (en) RECOMBINANT ONCOLYTIC VIRUS
DK3198017T3 (da) Virusbaserede ekspressionsvektorer og anvendelser deraf